scholarly journals Clinical application of the GLOBE and United Kingdom‐primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis

2018 ◽  
Vol 2 (6) ◽  
pp. 683-692 ◽  
Author(s):  
Marco Carbone ◽  
Maren H. Harms ◽  
Willem J. Lammers ◽  
Tonya Marmon ◽  
Richard Pencek ◽  
...  
Keyword(s):  
United Kingdom ◽  
Clinical Application ◽  
Risk Scores ◽  
Primary Biliary Cholangitis

scholarly journals External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid

2018 ◽  
Vol 2 (6) ◽  
pp. 676-682 ◽  
Author(s):  
Angela C. Cheung ◽  
Aliya F. Gulamhusein ◽  
Brian D. Juran ◽  
Erik M. Schlicht ◽  
Bryan M. McCauley ◽  
...  
Keyword(s):  
United Kingdom ◽  
Ursodeoxycholic Acid ◽  
External Validation ◽  
Risk Scores ◽  
Primary Biliary Cholangitis ◽  
The United Kingdom

scholarly journals A validation study of the 4-variable and 8-variable kidney failure risk equation in transplant recipients in the United Kingdom

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Ibrahim Ali ◽  
Philip A. Kalra
Keyword(s):  
United Kingdom ◽  
Kidney Failure ◽  
Graft Failure ◽  
Risk Scores ◽  
Transplant Recipients ◽  
Good Discrimination ◽  
Risk Equation ◽  
The United Kingdom ◽  
Failure Risk ◽  
Risk Patients

Abstract Background There is emerging evidence that the 4-variable Kidney Failure Risk Equation (KFRE) can be used for risk prediction of graft failure in transplant recipients. However, geographical validation of the 4-variable KFRE in transplant patients is lacking, as is whether the more extensive 8-variable KFRE improves predictive accuracy. This study aimed to validate the 4- and 8-variable KFRE predictions of the 5-year death-censored risk of graft failure in patients in the United Kingdom. Methods A retrospective cohort study involved 415 transplant recipients who had their first renal transplant between 2003 and 2015 and were under follow-up at Salford Royal NHS Foundation Trust. The KFRE risk scores were calculated on variables taken 1-year post-transplant. The area under the receiver operating characteristic curves (AUC) and calibration plots were evaluated to determine discrimination and calibration of the 4- and 8-variable KFREs in the whole cohort as well as in a subgroup analysis of living and deceased donor recipients and in patients with an eGFR< 45 ml/min/1.73m2. Results There were 16 graft failure events (4%) in the whole cohort. The 4- and 8-variable KFREs showed good discrimination with AUC of 0.743 (95% confidence interval [CI] 0.610–0.876) and 0.751 (95% CI 0.629–0.872) respectively. In patients with an eGFR< 45 ml/min/1.73m2, the 8-variable KFRE had good discrimination with an AUC of 0.785 (95% CI 0.558–0.982) but the 4-variable provided excellent discrimination in this group with an AUC of 0.817 (0.646–0.988). Calibration plots however showed poor calibration with risk scores tending to underestimate risk of graft failure in low-risk patients and overestimate risk in high-risk patients, which was seen in the primary and subgroup analyses. Conclusions Despite adequate discrimination, the 4- and 8-variable KFREs are imprecise in predicting graft failure in transplant recipients using data 1-year post-transplant. Larger, international studies involving diverse patient populations should be considered to corroborate these findings.

scholarly journals RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update

2018 ◽  
Vol 50 (4) ◽  
pp. 1474-1495 ◽  
Author(s):  
Rong-Quan He ◽  
Zhi-Guang Huang ◽  
Tian-Yu Li ◽  
Yan-Ping Wei ◽  
Gang Chen ◽  
...  
Keyword(s):  
Rna Sequencing ◽  
Clinical Application ◽  
Risk Score ◽  
In Silico ◽  
Differential Expression Analysis ◽  
Cox Proportional Hazards ◽  
The Cancer Genome Atlas ◽  
Risk Scores ◽  
Sequencing Data ◽  
Bioinformatics Analyses

Background/Aims: Current practical advances in high-throughput data technologies including RNA-sequencing have led to the identification of long non-coding RNAs (lncRNAs) for potential clinical application against bladder urothelial cancer (BLCA). However, most previous studies focused on the clinical value of individual lncRNAs, which has limited the potential for future clinical application. Methods: In this study, RNA-sequencing data of lncRNAs was downloaded from The Cancer Genome Atlas database. Risk score was constructed based on survival-associated lncRNAs identified using differential expression analysis as well as univariate and multivariate Cox proportional hazards regression analysis. Receiver operating characteristic and Kaplan-Meier curve analyses were employed to evaluate the clinical and prognostic value of risk scores. Bioinformatics analyses were used to investigate the potential mechanisms of newly identified lncRNAs. Results: Among 2,127 differentially expressed lncRNAs (DELs), four new lncRNAs (AC145124.1, AC010168.2, MIR200CHG, and AC098613.1) showed valuable prognostic effects in BLCA patients. More importantly, the four-DEL-based risk score had the potential to become an independent marker for the survival status prediction of BLCA patients. Distinct co-expressed genes and signaling pathways were identified when BLCA was categorized into low- and high-risk groups. Furthermore, a protein-coding gene, HIST4H4 was found only 68 bp from the AC010168.2 DEL. HIST4H4 expression level was evidently up-regulated and positively correlated with AC010168.2 in BLCA patients. Conclusion: This in silico investigation pioneers the future investigation of the utility of prognostic lncRNAs for BLCA.

scholarly journals The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis

Hepatology ◽  
2015 ◽  
Vol 63 (3) ◽  
pp. 930-950 ◽  
Author(s):  
Marco Carbone ◽  
Stephen J. Sharp ◽  
Steve Flack ◽  
Dimitrios Paximadas ◽  
Kelly Spiess ◽  
...  
Keyword(s):  
Liver Disease ◽  
Scoring System ◽  
Risk Scores ◽  
Primary Biliary Cholangitis ◽  
End Stage Liver Disease ◽  
Term Prediction ◽  
The Uk ◽  
End Stage ◽  
Long Term Prediction

Utility of UK-PBC Risk Scores as an Alternative to Transient Elastography in Assessing Risk in Primary Biliary Cholangitis (Cirrhosis) Patients

2016 ◽  
Vol 64 (2) ◽  
pp. S426-S427
Author(s):  
V.S. Hegade ◽  
A. Khanna ◽  
G. Pells ◽  
L.L. Wong ◽  
J.K. Dyson ◽  
...  
Keyword(s):  
Transient Elastography ◽  
Risk Scores ◽  
Primary Biliary Cholangitis

From Basic Science to Clinical Application of Polygenic Risk Scores

2020 ◽  
Author(s):  
Naomi R. Wray ◽  
Tian Lin ◽  
Jehannine Austin ◽  
John J. McGrath ◽  
Ian B. Hickie ◽  
...  
Keyword(s):  
Clinical Application ◽  
Basic Science ◽  
Risk Scores ◽  
Polygenic Risk

Application of Risk Scores in the Daily Management of Primary Biliary Cholangitis

2019 ◽  
Vol 114 (10) ◽  
pp. 1692
Author(s):  
Cumali Efe ◽  
Koray Taşçilar ◽  
Aldo J. Montano-Loza ◽  
Eric M. Yoshida ◽  
Staffan Wahlin
Keyword(s):  
Risk Scores ◽  
Primary Biliary Cholangitis

scholarly journals Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs

2020 ◽  
Vol 7 ◽  
Author(s):  
Apurva Shrivastava ◽  
Tina Haase ◽  
Tanja Zeller ◽  
Christian Schulte
Keyword(s):  
Heart Failure ◽  
Cardiac Function ◽  
Clinical Application ◽  
Complex Disease ◽  
Disease Risk ◽  
High Sensitivity ◽  
Risk Scores ◽  
Circular Rnas ◽  
True Value ◽  
Non Coding Rnas

Heart failure (HF) is a complex disease in which cardiomyocyte injury leads to a cascade of inflammatory and fibrosis pathway activation, thereby causing decrease in cardiac function. As a result, several biomolecules are released which can be identified easily in circulating body fluids. The complex biological processes involved in the development and worsening of HF require an early treatment strategy to stop deterioration of cardiac function. Circulating biomarkers provide not only an ideal platform to detect subclinical changes, their clinical application also offers the opportunity to monitor disease treatment. Many of these biomarkers can be quantified with high sensitivity; allowing their clinical application to be evaluated beyond diagnostic purposes as potential tools for HF prognosis. Though the field of biomarkers is dominated by protein molecules, non-coding RNAs (microRNAs, long non-coding RNAs, and circular RNAs) are novel and promising biomarker candidates that encompass several ideal characteristics required in the biomarker field. The application of genetic biomarkers as genetic risk scores in disease prognosis, albeit in its infancy, holds promise to improve disease risk estimation. Despite the multitude of biomarkers that have been available and identified, the majority of novel biomarker candidates are not cardiac-specific, and instead may simply be a readout of systemic inflammation or other pathological processes. Thus, the true value of novel biomarker candidates in HF prognostication remains unclear. In this article, we discuss the current state of application of protein, genetic as well as non-coding RNA biomarkers in HF risk prognosis.

Sign in / Sign up

Export Citation Format

Share Document